PositiveID to Use PCR Technology as Part of Shared Defense Contract with Leidos | GenomeWeb

NEW YORK (GenomeWeb) – Leidos and partner PositiveID have been awarded a contract from the US Defense Threat Reduction Agency (DTRA) to develop detection technologies for potential weapons of mass destruction.

Leidos is one of seven contractors eligible to compete for task orders under the DTRA contract, PositiveID said today. The multiple-award indefinite delivery/indefinite quantity contract has a five-year base period of performance, and if all options are exercised, it is valued at $4 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.